GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

Five GLP-1 medicines are FDA-approved for weight loss: Wegovy injection, the Wegovy pill, Zepbound, Foundayo and Saxenda. You generally qualify with a BMI of 30 or more, or 27 or more with a weight-related condition.

In trials, Wegovy injections averaged 14.9% weight loss and Zepbound up to 20.9%. Here is who qualifies, what each option costs and how to get a prescription.

April 13, 202612 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

Editorial lifestyle photograph illustrating a beginner guide to GLP-1 weight loss medications

Approved GLP-1 weight-loss labels generally use a BMI of 30+ (or 27+ with a weight-related condition), subject to the specific product label, and the approved injections produced 14.9% body weight loss for semaglutide in STEP-1 and up to 20.9% for tirzepatide in SURMOUNT-1 over 68-72 weeks. Those brand trials do not establish outcomes for compounded products.

Where to start, depending on what matters most to you:

For a bundled cash-pay option, Willow's GLP-1 program starts at $299/mo with care included; the exact price depends on the formulation and sometimes dose.

A lower advertised monthly price can also require a larger payment up front. bmiMD advertises compounded semaglutide at $159 for a one-month plan and tirzepatide at $249 for a one-month plan.

Its $119/mo and $179/mo rates require 12-month payments of $1,428 and $2,148, respectively. These public prices were checked September 26, 2026; confirm your prescribed product and full quote before paying.

This guide covers who qualifies, which medicine to choose, what each costs, side effects and the five steps to a prescription.

It draws on FDA prescribing information, published trial data and the prices we track for each telehealth program.

Know what to ask before choosing a program

The checklist covers care, medication and billing. When you're ready to compare programs, the finder narrows the list for you.

Use the provider checklist →

Which GLP-1 medications are FDA-approved for weight loss?

As of April 2026, the following GLP-1 receptor agonists are FDA-approved specifically for chronic weight management:

Which GLP-1 medications are FDA-approved for weight loss?
MedicationBrandDosingApproved
Orforglipron 0.8–17.2 mg tabletFoundayoDaily pill (no food restrictions)Apr 2026
Semaglutide 25mg oralWegovy (pill)Daily tablet (fasting required)Dec 2025
Tirzepatide injectionZepboundWeekly injectionNov 2023
Semaglutide 2.4mg injectionWegovyWeekly injectionJune 2021
Liraglutide 3.0mg injectionSaxendaDaily injectionDec 2014
Generic liraglutide (Teva)Generic SaxendaDaily injectionAug 2025
New in 2026:

Two oral GLP-1 agonists launched: Foundayo (orforglipron), FDA-approved April 1, 2026, has no food or water restrictions and starts at $149/month at 0.8 mg before its dose/refill ladder rises to as much as $349 (Foundayo dose and price ladder). Oral Wegovy (semaglutide 25mg), approved December 2025, requires fasting for 30 minutes before eating and is listed by NovoCare from $149/month, dose-dependent.

Their obesity results come from separate trials; compare them in Foundayo vs Wegovy Pill.

Ozempic and Mounjaro are FDA-approved only for Type 2 diabetes, not weight loss. However, doctors can and do prescribe them off-label for weight management.

If your provider prescribes Ozempic instead of Wegovy, this is legal but your insurance may not cover it for weight loss.

Who qualifies for a GLP-1?

You generally qualify for a GLP-1 weight-loss medicine with:

  • •BMI of 30 or higher (obesity), OR
  • •BMI of 27 or higher (overweight) with at least one weight-related health condition

Qualifying comorbidities include Type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, sleep apnea, non-alcoholic fatty liver disease (NAFLD), and PCOS, among others.

Wegovy is also approved for patients aged 12 and older with obesity. Insurers may apply stricter rules: some require a BMI of 35+, documented failed diet/exercise attempts, or prior authorization.

How to get a GLP-1 prescription in 5 steps

Getting a GLP-1 prescription involves an eligibility assessment, a clinician's decision and pharmacy fulfillment.

Intake length and delivery timing vary; completing a questionnaire does not guarantee a prescription or a delivery date.

  • •Step 1: Check if you qualify. FDA eligibility requires a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or fatty liver. Use our free eligibility checker to run the numbers in 30 seconds.
  • •Step 2: Choose a medication type. The main options are brand-name injectables (Wegovy, Zepbound) at $299-$449/mo self-pay, compounded injectables at $99-$250/mo cash-pay, or oral pills (Rybelsus, Wegovy pill, Foundayo) at $149-$649/mo. Read our brand vs compounded guide to understand the tradeoffs.
  • •Step 3: Pick a telehealth provider. Our rankings compare GLP-1 telehealth programs, and availability varies by state. Advertised entry points include Embody (compounded semaglutide from $79 on a selected plan), Enhance MD compounded plans (semaglutide or tirzepatide, with plan-specific billing terms), and Hers (Wegovy pill medication from $149 or pen from $199, plus required $39 first-month/$149 ongoing membership). Compare renewal rates and line items in our full cheapest ranking, or take the match quiz.
  • •Step 4: Complete the medical intake. Provide your medical history, current medications and weight-loss goals. The clinician decides whether treatment is appropriate and whether a live visit or further information is needed. Ask Shed, or any provider you choose, to distinguish clinical-review time, pharmacy processing and shipping transit; a transit estimate is not a promise of delivery within 2-3 days of signup. Our Trimi review shows how to check disclosed company and plan details before paying.
  • •Step 5: Start treatment. Medication ships directly to your home. You'll self-inject once weekly (for injectables) or take a daily pill (for orals) at the lowest starting dose. Dose escalation happens over 16-20 weeks. Read our first month on GLP-1 guide for a week-by-week timeline.
Short on time?

Our 7-question match quiz asks about your budget, medication preference, insurance status, and support needs, then recommends the best 3 providers for your specific situation.

How much weight can you lose on a GLP-1?

These are average results from large placebo-controlled trials, published in journals such as the New England Journal of Medicine.

How much weight can you lose on a GLP-1?
TrialMedicationDurationAvg Weight Loss
STEP 1Semaglutide 2.4mg68 weeks-14.9% body weight
STEP 5Semaglutide 2.4mg104 weeks (2 yr)-16.7%
STEP UPSemaglutide 7.2mg68 weeks-20.7%
OASIS 4Oral semaglutide 25mg64 weeks-13.6%
SURMOUNT-1Tirzepatide 15mg72 weeks-22.5%
SURMOUNT-5Tirzepatide vs Semaglutide72 weeks-20.2% vs -13.7%

In the STEP 1 trial, about 86% of participants on semaglutide 2.4mg achieved at least 5% weight loss, and roughly 51-64% lost 15% or more.

In SURMOUNT-1, 96% of participants on the 15mg tirzepatide dose achieved at least 5% weight loss, and 36% lost more than 25% of their body weight.

The head-to-head SURMOUNT-5 trial (published May 2025 in NEJM) showed tirzepatide produced significantly greater weight loss than semaglutide at maximum doses, 20.2% vs 13.7%.

Tirzepatide also had a lower rate of GI-related discontinuation (2.7% vs 5.6%).

What are the side effects?

GI side effects are the most common issue. From the Wegovy prescribing information and STEP trials:

What are the side effects?
Side EffectWegovyPlacebo
Nausea44%16%
Diarrhea30%16%
Vomiting25%6%
Constipation24%11%
Abdominal pain20%11%

Most of these were mild: 98.1% of GI side effects were mild to moderate. Only 4.1% of Wegovy patients reported severe GI reactions.

Side effects are worst during dose escalation (the first few weeks at each new dose level) and generally decrease over time. Every GLP-1 starts at a low dose and steps up to keep these effects down.

Important:

All GLP-1 medications carry a boxed warning about thyroid C-cell tumors based on rodent studies.

They're contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Rare but serious risks include pancreatitis and gallbladder problems.

How do you choose a GLP-1 provider?

Many people get a GLP-1 prescription through a telehealth program. When you compare programs, check:

  • •Medication options: Do they offer both brand-name and compounded? Brand-only? Only compounded?
  • •Clinical support: Is there ongoing physician oversight, or just an initial consultation?
  • •Insurance: Do they accept your insurance, or is it cash-pay only?
  • •Total cost: Monthly medication cost plus any consultation, lab work, or membership fees.
  • •Dose titration: Do they follow standard dose escalation schedules?

Fit and total cost can pull in different directions. AgelessRx, for example, offers GLP-1 options alongside a broader longevity-treatment menu, but its complete medication and clinical fees are not verified here.

Ask for the prescribed treatment, included care and full renewal charge in writing before comparing its headline price with another program.

We score and rank telehealth GLP-1 programs on our homepage. Check the rankings, or take the quiz to find a match for your budget.

How do GLP-1 medications work?

GLP-1 receptor agonists are synthetic versions of a gut hormone called glucagon-like peptide-1 (GLP-1) that your body naturally produces after eating. They work through three distinct mechanisms:

  • •Appetite suppression: They act on GLP-1 receptors in the hypothalamus, your brain's satiety center, reducing hunger signals. They also lower ghrelin (the "hunger hormone") and increase fullness hormones like peptide YY.
  • •Delayed gastric emptying: They slow how quickly food leaves your stomach, keeping you feeling full longer after meals.
  • •Glucose regulation: They stimulate insulin release and suppress glucagon from the pancreas, which is why they were originally developed for Type 2 diabetes.

Tirzepatide (sold as Zepbound and Mounjaro) goes further: it is a dual GIP/GLP-1 receptor agonist, activating two different incretin receptors simultaneously.

This dual mechanism may explain why tirzepatide consistently shows higher weight loss numbers in clinical trials.

Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Medicare & GLP-1

Medicare GLP-1 Coverage Guide

On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.

Read the Medicare guide →
Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss, which in turn lowers the risk of many weight-related conditions. These treatments also improve patients' quality of life in a meaningful way, making this a genuine win, win.”
Naveed Sattar, MD, PhD, Professor of Cardiometabolic Medicine
University of Glasgow
Expert reaction (Science Media Centre) to NICE draft guidance recommending semaglutide to prevent heart attacks and strokes.
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
Robert F. Kushner, MD, professor of medicine (endocrinology); STEP trial investigator
Northwestern University Feinberg School of Medicine
On the magnitude of semaglutide's effect vs older obesity drugs (STEP program).
“Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before. The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity.”
Louis J. Aronne, MD, obesity-medicine specialist; principal investigator, SURMOUNT-5 head-to-head trial
Weill Cornell Medicine
On the complete SURMOUNT-5 head-to-head results published in NEJM (tirzepatide vs semaglutide).

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.

Featured Partners

Affiliate partners we feature. We may earn a commission.

Embody

Embody illustration of a compounded semaglutide injection vial
from $49/mo·Compounded

Collective

Collective provider illustration of compounded semaglutide injection vial
from $59/mo + $199/year membership after 21 days·Compounded

Gala

Current program options·Brand & Compounded

Check the medication, commitment and total price for your selected plan.

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.